Therefore, understanding the mechanism on why tumor TLR9 expression levels remain low despite hypoxia in some TNBCs might open novel therapeutic possibilities that might also apply to renal cell carcinoma (30). This evidence concerns the gene TLR9 and renal cell carcinoma.